All right, already. So says GlaxoSmithKline to Mylan Pharmaceuticals, which has been fighting the company's patent on extended-release Paxil, an antidepressant. Glaxo gave Mylan the patent licenses that allow it to sell Paxil ER beginning in October 2008. Mylan got FDA approval for its version of the drug in June, and it'll have 180-day exclusivity once it starts selling.
- see Mylan's press release
- check out the report from CNN Money